Home・Aktien・Danaher Corp

Danaher Corp

Geschlossen

BrancheGesundheitswesen

202.44 -0.76

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

201

Max

203.87

Schlüsselkennzahlen
By Trading Economics
Einkommen	-159M 870M
Verkäufe	314M 6.3B
KGV Branchendurchschnitt	36.476 57.002
EPS	1.94
Dividendenrendite	0.7
Gewinnspanne	13.887
Angestellte	58,000
EBITDA	-364M 1.1B

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+7.79% upside

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	0.70% 2.22%
Nächstes Ergebnis	20. Okt. 2026
Nächste Dividendenausschüttung	30. Okt. 2026
Nächstes Ex-Dividendendatum	25. Sept. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	4.8B 147B
Vorheriger Eröffnungskurs	203.2
Vorheriger Schlusskurs	202.44

Nachrichtenstimmung

By Acuity

23%

77%

79 / 340 Ranking in Healthcare

Danaher Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Danaher Corp Prognose

Kursziel

By TipRanks

7.79% Vorteil

12-Monats-Prognose

Durchschnitt 219.78 USD 7.79%

Hoch 240 USD

Tief 195 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Danaher Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

Buy

Halten

Sell

Basierend auf 20 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Danaher Corp – Dist abgegeben haben.

Stimmung

By Acuity

79 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.